Moneycontrol
HomeNewsEconomyPolicyCoronavirus pandemic | India’s poor healthcare spending is hurting the fight

Coronavirus pandemic | India’s poor healthcare spending is hurting the fight

India has not paid enough attention to health services and Maharashtra, which has the highest COVID-19 cases, is the worst offender

April 09, 2020 / 10:26 IST
Story continues below Advertisement
Representative image

The adage that the sins of the past are heaped on the present is coming true. India is battling a coronavirus epidemic. It tried to stop its spread by announcing a nationwide 21-day lockdown as infections began to rise but without a supporting health infrastructure, the casualty rate is likely to go up.

India spent barely 1.29% of its gross domestic product (GDP) on healthcare in the financial year 2020, an April 7 report from CARE Ratings says. The spending on capital expenditure was worse, at only 0.19%.

Story continues below Advertisement

That perhaps explains why India did not do enough testing right from the start. The best managers of the coronavirus epidemic are acknowledged to be Germany, Japan, Singapore and South Korea, not necessarily in that order. What they did was to first test, followed it up by contact tracing and subsequently, isolation.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show